BCL2L1 and Thrombocytopenia: Consistent with previous findings of thrombocytopenia resulting from BCL-xL inhibition by Navitoclax [23, 24], we observed significant platelet reductions in all Navitoclax-treated animals, a side effect not seen with Venetoclax (Fig. 3K).